![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Enlivex Therapeutics Ltd | NASDAQ:ENLV | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.37 | 1.36 | 1.42 | 630 | 12:10:44 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 205499
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
September 24, 2008
ENLIVEN MARKETING TECHNOLOGIES CORPORATION
(Exact name of registrant as specified in its charter)
Delaware | 0-27168 | 95-4102687 | ||
(state or other juris- | (Commission | (I.R.S. Employer | ||
diction of incorporation) | File Number) | (Identification No.) | ||
205 West 39 th Street, 16 th Floor, New York, NY | 10018 | |||
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (212) 201-0800
N/A | ||
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[X] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On September 24, 2008, Enliven Marketing Technologies Corporation (the Company), held a special meeting of stockholders at which the stockholders of the Company approved the proposal to adopt the Agreement and Plan of Merger by and among DG FastChannel, Inc., a Delaware corporation, DG Acquisition Corp. VI., a Delaware corporation and a wholly owned subsidiary of DG FastChannel, Inc., and the Company, dated as of May 7, 2008, as amended by Amendment No. 1 dated as of September 4, 2008 (the Merger Agreement), and the merger contemplated thereby (the Merger). Approximately 99.5 percent of the shares of Company common stock voting on the proposal were voted in favor of the adoption of the Merger Agreement, representing approximately 77.5 percent of the issued and outstanding shares of Company common stock as of the close of business on August 7, 2008, the record date for the special meeting of stockholders. Closing of the Merger is scheduled for early October, 2008, subject to satisfaction or waiver of the closing conditions set forth in the Merger Agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ENLIVEN MARKETING TECHNOLOGIES | ||
CORPORATION | ||
/s/ Andrew J. Graf | ||
Andrew J. Graf | ||
Secretary |
Dated: September 25, 2008
1 Year Enlivex Therapeutics Chart |
1 Month Enlivex Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions